This was the stock's third consecutive day of gains.
After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.
Fintel on MSN17h
Raymond James Downgrades Vertex (VERX)Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to ...
Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings ...
Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...
DAR ES SALAAM: THE Bank of Tanzania’s (BoT) adjustment to the coupon rate determination method is poised to enhance investor confidence, creating a more attractive environment for fixed income ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback